Erbitux (cetuximab) Patient Assistance Program
Don’t let the high cost of brand anti-EGFR monoclonal antibody disrupt your colorectal or head and neck cancer treatment. We help eligible patients access Erbitux (cetuximab intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Erbitux (cetuximab) is FDA-approved for KRAS wild-type, EGFR-expressing metastatic colorectal cancer (in combination with FOLFIRI or irinotecan; or monotherapy after irinotecan- and oxaliplatin-based chemotherapy and a fluoropyrimidine), head and neck squamous cell carcinoma (with radiation in locally/regionally advanced or in combination with platinum-based therapy with 5-FU for recurrent/metastatic per EXTREME), and KRAS G12C-mutated CRC (in combination with KRAS G12C inhibitors per CodeBreaK 300/KRYSTAL-1). Anti-EGFR chimeric monoclonal antibody.
- Without assistance, Erbitux costs commonly run approximately $9,000–$14,000 per dose (weekly or biweekly depending on regimen).
- Through AffordMyPrescriptions, qualifying patients can access Erbitux for a flat $69.95 per month.
- Other anti-EGFR antibodies: panitumumab (Vectibix — fully human IgG2, fewer infusion reactions than Erbitux). KRAS testing essential — EGFR antibodies are ineffective in KRAS-mutated CRC. Other CRC therapies: bevacizumab (Avastin biosimilars now widely available — Mvasi, Zirabev), ramucirumab (Cyramza), aflibercept (Zaltrap), regorafenib (Stivarga generic), trifluridine/tipiracil (Lonsurf), encorafenib + cetuximab (BEACON for BRAF V600E), trastuzumab deruxtecan or T-DM1 for HER2+, Lynparza for BRCA-mutated, KRAS G12C inhibitors (Lumakras, Krazati with cetuximab). For H&N SCC: pembrolizumab (Keytruda — first-line for PD-L1 CPS≥1 per KEYNOTE-048).
What is Erbitux Prescription Assistance Program?
The Erbitux Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Erbitux (used for KRAS wild-type metastatic colorectal cancer and head and neck squamous cell carcinoma) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, medical or radiation oncology coordination, KRAS testing documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing advanced cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Erbitux PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including KRAS/NRAS/BRAF testing results, prior therapy history, and indication-specific criteria), follow up with the manufacturer’s program until approval, manage your infusion cycles, and handle annual re-certification — so you never face a gap in your Erbitux anti-EGFR therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Erbitux enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your colorectal or head and neck cancer treatment.
Pharmacy Price Comparison
- Without assistance, Erbitux costs thousands of dollars per infusion at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Erbitux advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic FOLFOX/FOLFIRI chemo | ~$500/cycle | Generic chemo backbone |
| Hospital oncology | ~$13,500/dose | Save substantially |
| Community oncology | ~$11,500/dose | Save substantially |
| Specialty pharmacy | ~$10,000/dose | Save substantially |
| 340B-eligible institution | ~$9,000/dose | Save substantially |
| Vectibix (alt anti-EGFR) | ~$10,500/dose | Alt anti-EGFR mAb |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Erbitux — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Erbitux Prescription Program?
The Erbitux Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. KRAS/NRAS/BRAF testing is essential for Erbitux candidacy — only KRAS wild-type CRC patients benefit.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Erbitux assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Erbitux is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Erbitux:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $9,000–$14,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Erbitux assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Erbitux Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Erbitux:
Erbitux is an anti-EGFR chimeric monoclonal antibody that binds and blocks the EGFR extracellular domain — preventing ligand binding and downstream RAS/MAPK proliferative signaling. Effective only in KRAS (and NRAS, BRAF) wild-type metastatic colorectal cancer — RAS pathway-activating mutations bypass EGFR blockade. Long-established standard in CRC, H&N SCC, and now also in combination with KRAS G12C inhibitors per recent trials.
How It Works:
EGFR is overexpressed or dysregulated in many epithelial cancers, driving proliferation, survival, angiogenesis, and metastasis. KRAS/NRAS/BRAF mutations downstream of EGFR bypass the receptor — making anti-EGFR antibodies ineffective in these patients. Cetuximab binds EGFR extracellular domain — blocks ligand binding, prevents receptor dimerization and downstream signaling, recruits ADCC. In KRAS wild-type CRC and H&N SCC, combination with chemotherapy or radiation produces meaningful survival benefit. Newer combinations with KRAS G12C inhibitors (Lumakras, Krazati) address EGFR-mediated feedback resistance in CRC. Skin rash (acneiform) is a class effect and surrogate of response.
Form and Use:
Erbitux IV infusion. Loading dose 400 mg/m² over 2 hours, then 250 mg/m² weekly over 1 hour. Alternative biweekly dosing 500 mg/m² every 2 weeks. Premedication with H1 antihistamine to reduce infusion reactions. Continue per protocol — combination cycles per regimen. Hold for infusion reactions, severe skin toxicity, ILD. Proactive skin care from cycle 1 (moisturizer, sunscreen, doxycycline 100 mg BID prophylaxis to reduce acneiform rash severity).
Generic Availability:
No biosimilar/generic. Other anti-EGFR antibodies: panitumumab (Vectibix — fully human IgG2, fewer infusion reactions than Erbitux but otherwise similar activity and indications). KRAS/NRAS/BRAF testing essential. Other metastatic CRC therapies: bevacizumab (Avastin with biosimilars now available — Mvasi, Zirabev), ramucirumab (Cyramza — anti-VEGFR2), aflibercept (Zaltrap), regorafenib (Stivarga generic), trifluridine/tipiracil (Lonsurf), encorafenib (Braftovi) + cetuximab (BEACON for BRAF V600E mutated CRC), trastuzumab deruxtecan (Enhertu) or T-DM1 (Kadcyla) for HER2-positive CRC, Lynparza for BRCA-mutated, KRAS G12C inhibitors (Lumakras/sotorasib, Krazati/adagrasib with cetuximab in CRC). Checkpoint inhibitors for MSI-H/dMMR (Keytruda, Opdivo + Yervoy per KEYNOTE-177 and CheckMate 8HW). Standard CRC chemotherapy backbones (generic): FOLFOX, FOLFIRI, FOLFOXIRI, capecitabine. For H&N SCC: pembrolizumab (Keytruda) ± chemotherapy first-line in recurrent/metastatic per KEYNOTE-048; nivolumab in platinum-refractory; standard radiotherapy with concurrent platinum-based chemoradiation; targeted therapies emerging.
Warnings:
Boxed warnings: infusion reactions (severe, sometimes fatal — premedicate and have emergency support; first-dose risk highest, especially in southern US due to alpha-gal antibody prevalence from tick exposure), cardiopulmonary arrest and sudden death (during or shortly after infusion — monitor electrolytes including magnesium, potassium, calcium; treat hypomagnesemia which is very common with anti-EGFR). Other: acneiform skin rash (very common — class effect, dose-dependent, can be severe; proactive skin care and prophylactic doxycycline reduce severity), paronychia, hair changes, hypomagnesemia (very common — monitor and replete), interstitial lung disease (sometimes fatal), severe mucocutaneous reactions including SJS/TEN (rare), dermatitis, infections, embryo-fetal toxicity. KRAS-mutated CRC: not effective — confirm KRAS/NRAS/BRAF wild-type status before treatment.
FAQ (Frequently Asked Questions)
How much does Erbitux cost without insurance?
$9,000–$14,000 per dose (weekly or biweekly). Annualized cost can exceed $200,000 depending on regimen and duration. Specialty pharmacy and Patient Assistance Programs are essential.
Why is KRAS testing required before starting Erbitux?
Anti-EGFR antibodies (Erbitux, Vectibix) are ineffective in KRAS-mutated colorectal cancer because KRAS mutations bypass the EGFR pathway. Extended RAS testing (KRAS exons 2/3/4 and NRAS exons 2/3/4) plus BRAF V600E testing identifies patients who will benefit. Approximately 45% of CRC is RAS wild-type.
What is the difference between Erbitux and Vectibix (panitumumab)?
Both anti-EGFR antibodies with similar mechanism and indications in RAS wild-type metastatic CRC. Erbitux is chimeric IgG1 — higher infusion reaction rate. Vectibix is fully human IgG2 — fewer infusion reactions, no premedication typically needed, biweekly dosing. Both effective.
Why does Erbitux cause acneiform skin rash and is it manageable?
EGFR is highly expressed in skin — blocking EGFR causes acneiform (papulopustular) rash, sometimes severe. The rash is dose-dependent and correlates with anti-tumor response. Proactive skin care from cycle 1 (moisturizers, sun protection, prophylactic doxycycline 100 mg BID, topical antibiotics) significantly reduces severity and impact on quality of life.
What are the FDA boxed warnings for Erbitux?
Severe infusion reactions (sometimes fatal — premedicate, monitor; highest risk in southern US due to alpha-gal antibody prevalence from tick exposure) and cardiopulmonary arrest/sudden death (during or shortly after infusion — monitor electrolytes, treat hypomagnesemia aggressively).
Take Control of Your Medication Costs
Anti-EGFR therapy for KRAS wild-type metastatic CRC and head/neck cancer should not be derailed by cost. KRAS/NRAS testing is essential. Our Erbitux advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Erbitux through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.